keyword
MENU ▼
Read by QxMD icon Read
search

Triple-H therapy

keyword
https://www.readbyqxmd.com/read/28079669/the-irish-helicobacter-pylori-working-group-consensus-for-the-diagnosis-and-treatment-of-h-pylori-infection-in-adult-patients-in-ireland
#1
Sinead Smith, Breida Boyle, Denise Brennan, Martin Buckley, Paul Crotty, Maeve Doyle, Richard Farrell, Mary Hussey, David Kevans, Peter Malfertheiner, Francis Megraud, Sean Nugent, Anthony O'Connor, Colm O'Morain, Shiobhan Weston, Deirdre McNamara
BACKGROUND: Irish eradication rates for Helicobacter pylori are decreasing and there is an increase in the prevalence of antibiotic-resistant bacteria. These trends call into question current management strategies. OBJECTIVE: To establish an Irish Helicobacter pylori Working Group (IHPWG) to assess, revise and tailor current available recommendations. METHODS: Experts in the areas of gastroenterology and microbiology were invited to join the IHPWG...
January 10, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28077338/10-day-bismuth-containing-quadruple-therapy-is-effective-as-first-line-therapy-for-helicobacter-pylori-related-chronic-gastritis-a-prospective-randomized-study-in-china
#2
Liangjing Wang, Zhenghua Lin, Shujie Chen, Jun Li, Chun Xiao Chen, Zhiming Huang, Bin Ye, Jin Ding, Wei Li, Lunpo Wu, Ying Jiang, Lina Meng, Qin Du, Jianmin Si
OBJECTIVES: To investigate the effectiveness of 10-day bismuth-containing quadruple (B-quadruple) treatment as first-line therapy in patients with Helicobacter pylori related chronic gastritis. METHODS: Randomized control trial conducted from Oct. 2011 to Dec. 2013 in Zhejiang, China, including patients with H. pylori-related chronic gastritis who were randomly given either 10-day omeprazole-based triple (OM-triple, omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1g twice daily), or 10-day B-quadruple therapy (OM-triple + bismuth subcitrate 120 mg four times daily)...
January 7, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28072642/acute-neuropsychiatric-symptoms-associated-with-antibiotic-treatment-of-helicobacter-pylori-infections-a-review
#3
Nicholas H Neufeld, Nourhan S Mohamed, Nikola Grujich, Kenneth Shulman
Helicobacter pylori infects half the global population. Because serious complications can result from this infection, a so-called "triple therapy" is recommended: treatment with a proton-pump inhibitor and clarithromycin, along with amoxicillin or metronidazole. Although these antibiotics have been associated with neuropsychiatric symptoms, it is difficult to disentangle the effects of antibiotics from the effects of acute infections that may precipitate acute neuropsychiatric symptoms. Study of patients with chronic H...
January 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28071659/acg-clinical-guideline-treatment-of-helicobacter-pylori-infection
#4
William D Chey, Grigorios I Leontiadis, Colin W Howden, Steven F Moss
Helicobacter pylori (H. pylori) infection is a common worldwide infection that is an important cause of peptic ulcer disease and gastric cancer. H. pylori may also have a role in uninvestigated and functional dyspepsia, ulcer risk in patients taking low-dose aspirin or starting therapy with a non-steroidal anti-inflammatory medication, unexplained iron deficiency anemia, and idiopathic thrombocytopenic purpura. While choosing a treatment regimen for H. pylori, patients should be asked about previous antibiotic exposure and this information should be incorporated into the decision-making process...
January 10, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28049442/analyzing-the-influence-of-gastric-intestinal-metaplasia-on-gastric-ulcer-healing-in-helicobacter-pylori-infected-patients-without-atrophic-gastritis
#5
Li-Wei Chen, Liang-Che Chang, Chung-Ching Hua, Bor-Jen Hsieh, Shuo-Wei Chen, Rong-Nan Chien
BACKGROUND: Gastric epithelial hyper-proliferation was reported in patients with Helicobacter pylori (H. pylori)-infected gastric mucosa with intestinal metaplasia (IM) changes. In patients with gastric ulcer (GU) and IM, the GU may have a different healing rate in comparison to patients without IM. This study aimed to compare the difference in GU healing between H. pylori-infected patients with IM and those without IM. METHODS: We retrospectively analyzed patients at the Keelung Chung Gung Memorial Hospital during the period from March 2005 to January 2011...
January 3, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28018788/efficacy-of-triple-antiemetic-therapy-palonosetron-dexamethasone-aprepitant-for-chemotherapy-induced-nausea-and-vomiting-in-patients-receiving-carboplatin-based-moderately-emetogenic-chemotherapy
#6
Toshimichi Miya, Kunihiko Kobayashi, Mitsunori Hino, Masahiro Ando, Susumu Takeuchi, Masahiro Seike, Kaoru Kubota, Akihiko Gemma
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is a major adverse toxicity of cancer chemotherapy. Recommended treatments for prevention of CINV vary among published guidelines, and optimal care for CINV caused by moderately emetogenic chemotherapy has not been established. This study assessed the efficacy and safety of triple antiemetic therapy comprising palonosetron, dexamethasone and aprepitant for carboplatin-based chemotherapy. Chemotherapy-naïve patients with lung cancer scheduled for a first course of a carboplatin-containing regimen formed the study cohort...
2016: SpringerPlus
https://www.readbyqxmd.com/read/28013116/low-risk-of-pneumonia-from-pneumocystis-jirovecii-infection-in-patients-with-inflammatory-bowel-disease-receiving-immune-suppression
#7
Thomas G Cotter, Nicola Gathaiya, Jelena Catania, Edward V Loftus, William J Tremaine, Larry M Baddour, W Scott Harmsen, Alan R Zinsmeister, William J Sandborn, Andrew H Limper, Darrell S Pardi
BACKGROUND & AIMS: Use of immunosuppressants and inflammatory bowel disease (IBD) may increase the risk of pneumonia caused by Pneumocystis jirovecii (PJP). We assessed the risk of PJP in a population-based cohort of patients with IBD treated with corticosteroids, immune-suppressive medications, and biologics. METHODS: We performed a population-based cohort study of residents of Olmsted County, Minnesota, diagnosed with Crohn's disease (n=427) or ulcerative colitis (n=510) from 1970 through 2011...
December 21, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28012411/omitting-radiation-therapy-in-women-with-triple-negative-breast-cancer-leads-to-worse-breast-cancer-specific-survival
#8
I Kindts, P Buelens, A Laenen, E Van Limbergen, H Janssen, H Wildiers, C Weltens
PURPOSE: To examine locoregional recurrence (LRR) and breast cancer-specific survival (BCSS) after breast-conserving therapy (BCT) or mastectomy (ME) with or without radiation therapy (RT) in triple-negative breast cancer (TNBC). MATERIAL & METHODS: We identified non-metastatic TNBC cases from a single institution database. BCT, ME with RT (ME + RT) and ME only were compared with respect to LRR and BCSS. Cox regression models were used to analyze the association between prognostic factors and outcome...
December 21, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27999644/comparison-of-levofloxacin-versus-clarithromycin-efficacy-in-the-eradication-of-helicobacter-pylori-infection
#9
Ali Akbar Haji-Aghamohammadi, Ali Bastani, Arash Miroliaee, Sonia Oveisi, Saeed Safarnezhad
BACKGROUND: Helicobacter pylori (H.pylori) infection causes multiple upper gastrointestinal diseases but optimal therapeutic regimen which can eradicate infection in all the cases has not yet been defined. This study was designed to evaluate the efficacy of triple levofloxacin-based versus clarithromycin-based therapy. METHODS: In this open-label randomized clinical trial study 120 patients who had esophagogastroduodenoscopy (EGD) with positive rapid urease test (RUT) were enrolled and divided into 2 groups...
2016: Caspian Journal of Internal Medicine
https://www.readbyqxmd.com/read/27996373/helicobacter-pylori-primary-antibiotic-resistance-in-2015-in-morocco-a-phenotypic-and-genotypic-prospective-and-multicenter-study
#10
Najat Bouihat, Christophe Burucoa, Ahmed Benkirane, Hassan Seddik, Sara Sentissi, Abderrahmane Al Bouzidi, Mustapha Elouennas, Amina Benouda
Knowledge of local antibiotic resistance is crucial to adaption of the choice of effective empirical first-line treatment for Helicobacter pylori infection. The aim of this study was to evaluate, for the first time in Morocco, the prevalence of the primary resistance of H. pylori to clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and rifamycin. We conducted a 1-year prospective study (2015), including 255 Moroccan patients referred for gastro-duodenal endoscopy to two hospitals of Rabat (Morocco) and never previously treated for H...
December 20, 2016: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/27994474/probiotics-improve-the-efficacy-of-standard-triple-therapy-in-the-eradication-of-helicobacter-pylori-a-meta-analysis
#11
Christine S M Lau, Amanda Ward, Ronald S Chamberlain
INTRODUCTION: Helicobacter pylori colonization is present in half of the world's population and can lead to numerous gastrointestinal diseases if left untreated, including peptic ulcer disease and gastric cancer. Although concurrent triple therapy remains the recommended treatment regimen for H. pylori eradication, its success rate and efficacy have been declining. Recent studies have shown that the addition of probiotics can significantly increase eradication rates by up to 50%. This meta-analysis examines the impact of probiotic supplementation on the efficacy of standard triple therapy in eradicating H...
2016: Infection and Drug Resistance
https://www.readbyqxmd.com/read/27988794/teriparatide-treatment-in-a-heart-transplant-patient-with-a-chronic-kidney-disease-and-a-low-turnover-bone-disease-a-case-report
#12
A Fahrleitner-Pammer, D Wagner, P Krisper, K Amrein, H Dimai
Low-turnover bone disease is a complication of chronic kidney disease and a long-term steroid therapy. Currently, the only bone anabolic treatment available is teriparatide (TPTD). So far, no data exist in heart transplant patients, and only one single case with histomorphometric analysis of a dialysis patient with a low-turnover bone disease has been published. The current report shows the effect of a 1-year TPTD therapy in a cardiac transplant patient with 10 vertebral and 3 peripheral fractures who had developed a chronic kidney failure while receiving triple immunosuppressive therapy...
December 17, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27982354/genetic-mutations-affecting-the-first-line-eradication-therapy-of-helicobacter-pylori-infected-egyptian-patients
#13
Iman Ramzy, Hassan Elgarem, Iman Hamza, Doaa Ghaith, Tamer Elbaz, Waleed Elhosary, Gehan Mostafa, Mohammad A Mohey Eldin Elzahry
Introduction: Several genetic mutations affect the first-line triple therapy for Helicobacter pylori. We aimed to study the most common genetic mutations affecting the metronidazole and clarithromycin therapy for H. pylori-infected Egyptian patients. Patients and Methods: In our study, we included 100 successive dyspeptic patients scheduled for diagnosis through upper gastroscopy at Cairo's University Hospital, Egypt. Gastric biopsies were tested for the presence of H...
December 8, 2016: Revista do Instituto de Medicina Tropical de São Paulo
https://www.readbyqxmd.com/read/27979916/combination-epigenetic-therapy-in-advanced-breast-cancer-with-5-azacitidine-and-entinostat-a-phase-ii-national-cancer-institute-stand-up-to-cancer-study
#14
Roisin Connolly, Huili Li, Rachel C Jankowitz, Zhe Zhang, Michelle A Rudek, Stacie C Jeter, Shannon Slater, Penny Powers, Antonio C Wolff, John H Fetting, Adam M Brufsky, Richard Piekarz, Nita Ahuja, Peter W Laird, Hui Shen, Daniel J Weisenberger, Leslie Cope, James G Herman, George Somlo, Agustin Garcia, Peter A Jones, Stephen B Baylin, Nancy E Davidson, Cynthia Zahnow, Vered Stearns
PURPOSE: In breast cancer models, combination epigenetic therapy with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor led to re-expression of genes encoding important therapeutic targets including the estrogen receptor (ER). We conducted a multicenter phase II study of 5-azacitidine (AZA) and entinostat in women with advanced hormone-resistant or triple-negative breast cancer (TNBC). PATIENTS AND METHODS: Patients received AZA 40 mg/m2 (days 1-5, 8-10) and entinostat 7 mg (days 3,10) of 28 day cycle...
December 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27974577/uncovering-emergent-interactions-in-three-way-combinations-of-stressors
#15
Casey Beppler, Elif Tekin, Zhiyuan Mao, Cynthia White, Cassandra McDiarmid, Emily Vargas, Jeffrey H Miller, Van M Savage, Pamela J Yeh
Understanding how multiple stressors interact is needed to predict the dynamical outcomes of diverse biological systems, ranging from drug-resistant pathogens that are combated and treated with combination drug therapies to ecosystems impacted by environmental toxicants or disturbances. Nevertheless, extensive studies of higher-order (more than two component) interactions have been lacking. Here, we conduct experiments using 20 three-drug combinations and their effects on the bacterial growth of Escherichia coli We report our measurements of growth rates in single, pairwise and triple-drug combinations...
December 2016: Journal of the Royal Society, Interface
https://www.readbyqxmd.com/read/27935867/the-bromodomain-inhibitor-otx015-mk-8628-exerts-anti-tumor-activity-in-triple-negative-breast-cancer-models-as-single-agent-and-in-combination-with-everolimus
#16
Ramiro Vázquez, María E Riveiro, Lucile Astorgues-Xerri, Elodie Odore, Keyvan Rezai, Eugenio Erba, Nicolò Panini, Andrea Rinaldi, Ivo Kwee, Luca Beltrame, Mohamed Bekradda, Esteban Cvitkovic, Francesco Bertoni, Roberta Frapolli, Maurizio D'Incalci
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subgroup of breast tumors clinically defined by the lack of estrogen, progesterone and HER2 receptors, limiting the use of the targeted therapies employed in other breast malignancies. Recent evidence indicates that c-MYC is a key driver of TNBC. The BET-bromodomain inhibitor OTX015 (MK-8628) has potent antiproliferative activity accompanied by c-MYC down-regulation in several tumor types, and has demonstrated synergism with the mTOR inhibitor everolimus in different models...
December 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27923592/developments-in-targeted-therapy-in-melanoma
#17
REVIEW
V C Amann, E Ramelyte, S Thurneysen, R Pitocco, N Bentele-Jaberg, S M Goldinger, R Dummer, J Mangana
Melanomas are disease entities driven in part by the mitogen activated protein kinase (MAPK) pathway. The TCGA network recently defined four genetic subtypes based on the most prevalent significantly mutated genes, including mutant BRAF, mutant RAS (N/H/K), mutant NF1, and Triple wild-type melanoma (harboring none of the aforementioned mutations, but instead includes KIT, GNA and GNAQ mutations). The successful development of kinase inhibitors marked a milestone in the treatment of metastatic melanoma. Combination treatment with a BRAF- and MEK-inhibitor is the current standard of care for inoperable stage IIIC/IV BRAF-mutated melanoma...
November 5, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27913991/24-hour-efficacy-and-ocular-surface-health-with-preservative-free-tafluprost-alone-and-in-conjunction-with-preservative-free-dorzolamide-timolol-fixed-combination-in-open-angle-glaucoma-patients-insufficiently-controlled-with-preserved-latanoprost-monotherapy
#18
Anastasios-Georgios Konstas, Konstadinos G Boboridis, Paraskevas Kapis, Konstantinos Marinopoulos, Irini C Voudouragkaki, Dimitrios Panayiotou, Dimitrios G Mikropoulos, Eirini Pagkalidou, Anna-Bettina Haidich, Andreas Katsanos, Luciano Quaranta
INTRODUCTION: The aim of the present study was to evaluate the 24-h efficacy, tolerability, and ocular surface health with preservative-free (PF) tafluprost and a PF triple drug regimen comprising tafluprost and dorzolamide/timolol fixed combination (DTFC) in open-angle glaucoma patients who were insufficiently controlled with preserved branded or generic latanoprost monotherapy and who exhibited signs or symptoms of ocular surface disease (OSD). METHODS: Prospective, observer-masked, crossover, comparison...
December 2, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27906990/surveillance-of-helicobacter-pylori-antibiotic-susceptibility-in-indonesia-different-resistance-types-among-regions-and-with-novel-genetic-mutations
#19
Muhammad Miftahussurur, Ari Fahrial Syam, Iswan Abbas Nusi, Dadang Makmun, Langgeng Agung Waskito, Lukman Hakim Zein, Fardah Akil, Willy Brodus Uwan, David Simanjuntak, I Dewa Nyoman Wibawa, Jimmy Bradley Waleleng, Alexander Michael Joseph Saudale, Fauzi Yusuf, Syifa Mustika, Pangestu Adi, Ummi Maimunah, Hasan Maulahela, Yudith Annisa Ayu Rezkitha, Phawinee Subsomwong, Nasronudin, Dadik Rahardjo, Rumiko Suzuki, Junko Akada, Yoshio Yamaoka
Information regarding Helicobacter pylori antibiotic resistance in Indonesia was previously inadequate. We assessed antibiotic susceptibility for H. pylori in Indonesia, and determined the association between virulence genes or genetic mutations and antibiotic resistance. We recruited 849 dyspeptic patients who underwent endoscopy in 11 cities in Indonesia. E-test was used to determine the minimum inhibitory concentration of five antibiotics. PCR-based sequencing assessed mutations in 23S rRNA, rdxA, gyrA, gyrB, and virulence genes...
2016: PloS One
https://www.readbyqxmd.com/read/27899956/innovations-that-reach-the-patient-early-health-technology-assessment-and-improving-the-chances-of-coverage-and-implementation
#20
W H van Harten, V P Retèl
With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer...
2016: Ecancermedicalscience
keyword
keyword
49252
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"